Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Malignant Lymphoma

Free Subscription Articles published in Bone Marrow Transplant Retrieve available abstracts of 82 articles: HTML format

Single Articles

April 2024
1. DONADEL CD, De Santis GC, Goncalves TE, Pires BG, et al
   Safety and efficacy of a new academic CD19-directed CAR-T cell for refractory/relapsed non-Hodgkin lymphoma and acute lymphoblastic leukemia in Brazil.
   Bone Marrow Transplant. 2024 Apr 13. doi: 10.1038/s41409-024-02283.
   PubMed    
   
   
   March 2024
2. GIRARD L, Koh YJ, Koh LP, Chee YL, et al
   Role of upfront autologous transplant for peripheral T-cell lymphoma patients achieving a complete remission with first-line therapy: a systematic review and meta-analysis.
   Bone Marrow Transplant. 2024 Mar 5. doi: 10.1038/s41409-024-02254.
   PubMed     Abstract available
   
   
   February 2024
3. NAKAYA Y, Nakamae H, Nishikubo M, Kondo E, et al
   Peripheral blood stem cell transplantation using HLA-haploidentical donor with post-transplant cyclophosphamide versus HLA-matched sibling donor for lymphoma.
   Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02229.
   PubMed     Abstract available
   
   
   
4. HIROSE A, Koh H, Nakamae M, Nakashima Y, et al
   A comparison of long-term outcomes by donor type in the era of post-transplantation cyclophosphamide for aggressive adult T-cell leukemia/lymphoma.
   Bone Marrow Transplant. 2024 Feb 14. doi: 10.1038/s41409-024-02231.
   PubMed    
   
   
   
5. MOSER O, Ngoya M, Galimard JE, Dalissier A, et al
   Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study.
   Bone Marrow Transplant. 2024 Feb 8. doi: 10.1038/s41409-024-02226.
   PubMed     Abstract available
   
   
   
6. AHMADI P, Ghandili S, Jakobs F, Konnopka C, et al
   Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective.
   Bone Marrow Transplant. 2024 Feb 6. doi: 10.1038/s41409-024-02228.
   PubMed    
   
   
   January 2024
7. DE PHILIPPIS C, Zucchinetti C, Mannina D, Krampera M, et al
   Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma.
   Bone Marrow Transplant. 2024 Jan 25. doi: 10.1038/s41409-024-02205.
   PubMed    
   
   
   
8. CHEN W, Shi J, Luo Y, Yu J, et al
   Selective histone deacetylase inhibitor after allo-HCT for T-cell acute lymphoblastic leukemia or T-cell lymphoma.
   Bone Marrow Transplant. 2024 Jan 23. doi: 10.1038/s41409-023-02191.
   PubMed    
   
   
   
9. NABERGOJ M, Eikema DJ, Koster L, Platzbecker U, et al
   Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT.
   Bone Marrow Transplant. 2024 Jan 9. doi: 10.1038/s41409-023-02193.
   PubMed     Abstract available
   
   
   
10. OLUWOLE OO, Forcade E, Munoz J, de Guibert S, et al
    Long-term outcomes of patients with large B-cell lymphoma treated with axicabtagene ciloleucel and prophylactic corticosteroids.
    Bone Marrow Transplant. 2024 Jan 4. doi: 10.1038/s41409-023-02169.
    PubMed     Abstract available
    
    
    
11. CABRERO M, Lopez-Corral L, Jarque I, de la Cruz-Vicente F, et al
    Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial.
    Bone Marrow Transplant. 2024 Jan 2. doi: 10.1038/s41409-023-02171.
    PubMed     Abstract available
    
    
    December 2023
12. ZHANG X, Pang Y, Wei C, Liang D, et al
    Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.
    Bone Marrow Transplant. 2023 Dec 23. doi: 10.1038/s41409-023-02182.
    PubMed    
    
    
    
13. EL WARRAK S, Kharfan-Dabaja MA, Iqbal M, Hamadani M, et al
    Therapeutic options for large B-cell lymphoma relapsing after CD19-directed CAR T-cell therapy.
    Bone Marrow Transplant. 2023 Dec 16. doi: 10.1038/s41409-023-02176.
    PubMed     Abstract available
    
    
    
14. JINDAL N, C M, Mathew LJ, Kumbhalwar K, et al
    Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02179.
    PubMed    
    
    
    
15. KATO K, Sugio T, Ikeda T, Yoshitsugu K, et al
    Outcomes of allogeneic hematopoietic stem cell transplantation for relapsed or refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2023 Dec 15. doi: 10.1038/s41409-023-02156.
    PubMed     Abstract available
    
    
    November 2023
16. IQBAL M, Jagadeesh D, Chavez J, Khurana A, et al
    Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy.
    Bone Marrow Transplant. 2023 Nov 16. doi: 10.1038/s41409-023-02148.
    PubMed     Abstract available
    
    
    
17. PENA M, Montane C, Paviglianiti A, Hurtado L, et al
    Outcomes of allogeneic hematopoietic cell transplantation after bispecific antibodies in non-Hodgkin lymphomas.
    Bone Marrow Transplant. 2023;58:1282-1285.
    PubMed    
    
    
    October 2023
18. GOYAL A, O'Leary D, Foss F
    Allogeneic stem cell transplant for treatment of mycosis fungoides and Sezary syndrome: a systematic review and meta-analysis.
    Bone Marrow Transplant. 2023 Oct 18. doi: 10.1038/s41409-023-02122.
    PubMed     Abstract available
    
    
    
19. KORESAWA-SHIMIZU R, Suzuki R, Uehara Y, Hiramoto N, et al
    Comparison of MEAM, MCEC and LEED high-dose chemotherapy followed by autologous stem cell transplantation in relapsed/refractory diffuse large B-cell lymphoma: data from the Japan Society for Hematopoietic and Cellular Therapy Registry.
    Bone Marrow Transplant. 2023 Oct 7. doi: 10.1038/s41409-023-02118.
    PubMed    
    
    
    September 2023
20. ALEIXO GFP, Wei W, Chen PH, Gandhi NS, et al
    The association of body composition and outcomes following autologous hematopoietic stem cell transplantation in patients with non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Sep 12. doi: 10.1038/s41409-023-02104.
    PubMed     Abstract available
    
    
    
21. BAUR K, Buser A, Jeker LT, Khanna N, et al
    CD4+ CAR T-cell expansion is associated with response and therapy related toxicities in patients with B-cell lymphomas.
    Bone Marrow Transplant. 2023;58:1048-1050.
    PubMed    
    
    
    August 2023
22. WANG J, Alkrekshi A, Dasari S, Lin HC, et al
    CD19-targeted chimeric antigen receptor T-cell therapy in patients with concurrent B-cell Non-Hodgkin lymphoma and rheumatic autoimmune diseases: a propensity score matching study.
    Bone Marrow Transplant. 2023 Aug 21. doi: 10.1038/s41409-023-02086.
    PubMed     Abstract available
    
    
    
23. BACHANOVA V, Nachman PH
    Two for one? CAR-T therapy for lymphoma benefits concurrent autoimmune disorders.
    Bone Marrow Transplant. 2023 Aug 19. doi: 10.1038/s41409-023-02084.
    PubMed    
    
    
    
24. ARSHAD S, Fang X, Ahn KW, Kaur M, et al
    Impact of thiotepa dose-intensity in primary diffuse large B-cell lymphoma of the central nervous system undergoing autologous hematopoietic cell transplant with thiotepa/carmustine conditioning.
    Bone Marrow Transplant. 2023 Aug 10. doi: 10.1038/s41409-023-02071.
    PubMed     Abstract available
    
    
    
25. STYCZYNSKI J, Tridello G, Koster L, Knelange N, et al
    Decrease of lethal infectious complications in the context of causes of death (COD) after hematopoietic cell transplantation: COD-2 and COD-1 study of the Infectious Diseases Working Party EBMT.
    Bone Marrow Transplant. 2023;58:881-892.
    PubMed     Abstract available
    
    
    July 2023
26. DAMLAJ M, Tlayjeh M, Damlaj A, Alahmari B, et al
    Contemporary outcomes of high risk relapsed refractory classical hodgkin lymphoma patients-role of maintenance therapy in the real world.
    Bone Marrow Transplant. 2023 Jul 18. doi: 10.1038/s41409-023-02036.
    PubMed    
    
    
    June 2023
27. OTHMAN T, Lowsky R, Richman C, Hoeg R, et al
    Yttrium-90 ibritumomab tiuxetan plus ATG/TLI for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2023 Jun 30. doi: 10.1038/s41409-023-02025.
    PubMed    
    
    
    
28. MUSSETTI A, Bento L, Bastos-Oreiro M, Rius-Sansalvador B, et al
    Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era.
    Bone Marrow Transplant. 2023;58:673-679.
    PubMed     Abstract available
    
    
    May 2023
29. AL-JUHAISHI T, Wang Y, Milton DR, Xu-Monette ZY, et al
    Clinical relevance of MYC/BCL2 expression and cell of origin in patients with diffuse large b-cell lymphoma treated with autologous transplant.
    Bone Marrow Transplant. 2023 May 18. doi: 10.1038/s41409-023-02006.
    PubMed     Abstract available
    
    
    
30. INOUE Y, Morishima S, Kato K, Ito A, et al
    Impact of HLA-mismatched unrelated transplantation in patients with adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2023 May 12. doi: 10.1038/s41409-023-02002.
    PubMed     Abstract available
    
    
    April 2023
31. PORTUGUESE AJ, Gauthier J, Tykodi SS, Hall ET, et al
    CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic review.
    Bone Marrow Transplant. 2023;58:353-359.
    PubMed     Abstract available
    
    
    March 2023
32. FUJI S, Inoue Y, Makiyama J, Nakano N, et al
    The clinical benefit of acute GVHD depends on the age at transplantation in patients with adult T-cell leukemia-lymphoma on behalf of the ATL Working Group of the Japan Society for Transplantation and Cellular Therapy.
    Bone Marrow Transplant. 2023 Mar 25. doi: 10.1038/s41409-023-01969.
    PubMed    
    
    
    February 2023
33. MIAN A, Wei W, Hamilton BK, Winter AM, et al
    Resource utilization in patients with large B-cell lymphoma receiving tisagenlecleucel and axicabtagene ciloleucel.
    Bone Marrow Transplant. 2023 Feb 11. doi: 10.1038/s41409-023-01934.
    PubMed    
    
    
    January 2023
34. TOKUNAGA M, Nakano N, Fuji S, Wake A, et al
    Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study.
    Bone Marrow Transplant. 2023 Jan 21. doi: 10.1038/s41409-023-01919.
    PubMed    
    
    
    December 2022
35. YANG F, Shi H, Xu T, Liu R, et al
    Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma.
    Bone Marrow Transplant. 2022 Dec 22. doi: 10.1038/s41409-022-01903.
    PubMed    
    
    
    
36. ALSULIMAN T, Stocker N, Corre E, Dulery R, et al
    Autologous hematopoietic cell transplantation as a part of a sequential multi-phase therapeutic approach (R-COPADM/CYVE/ASCT) as first-line treatment of high-grade B-cell lymphoma: results of a retrospective study with long-term follow-up.
    Bone Marrow Transplant. 2022 Dec 22. doi: 10.1038/s41409-022-01902.
    PubMed     Abstract available
    
    
    
37. LIU W, Ji J, Zou D, Cao Y, et al
    Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China.
    Bone Marrow Transplant. 2022 Dec 17. doi: 10.1038/s41409-022-01899.
    PubMed    
    
    
    
38. YING Z, Xie Y, Zheng W, Liu W, et al
    Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin's lymphoma: 2-year results of a phase 1 trial.
    Bone Marrow Transplant. 2022 Dec 7. doi: 10.1038/s41409-022-01888.
    PubMed     Abstract available
    
    
    November 2022
39. DREGER P, Holtick U, Subklewe M, von Tresckow B, et al
    Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience.
    Bone Marrow Transplant. 2022 Nov 22. doi: 10.1038/s41409-022-01867.
    PubMed    
    
    
    September 2022
40. TANG B, Cai Z, Wang Z, Lin D, et al
    Allogeneic hematopoietic stem cell transplantation overcome the poor prognosis of patients with IKZF1plus CD20-a very high-risk subtype in B-cell acute lymphoblastic leukemia.
    Bone Marrow Transplant. 2022 Sep 2. pii: 10.1038/s41409-022-01797.
    PubMed     Abstract available
    
    
    August 2022
41. ELLIOTT J, Ahlawat S, Prince HM, Kennedy G, et al
    Long-term outcomes for allogeneic bone marrow transplantation in Sezary syndrome and mycosis fungoides.
    Bone Marrow Transplant. 2022 Aug 26. pii: 10.1038/s41409-022-01787.
    PubMed    
    
    
    
42. JACOBSEN ED, Kim HT, Jeter E, Jacobson C, et al
    Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma.
    Bone Marrow Transplant. 2022 Aug 22. pii: 10.1038/s41409-022-01784.
    PubMed    
    
    
    
43. HANNA P, Strohbehn I, Moreno D, Harden D, et al
    Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma.
    Bone Marrow Transplant. 2022 Aug 3. pii: 10.1038/s41409-022-01767.
    PubMed    
    
    
    July 2022
44. MA J, Sun S, Hu Y, Wu M, et al
    Novel conditioning regimen in upfront autologous stem cell transplantation in high-risk DLBCL.
    Bone Marrow Transplant. 2022 Jul 25. pii: 10.1038/s41409-022-01766.
    PubMed    
    
    
    June 2022
45. MEISSNER J, Schmitt M, Andrulis M, Schweizer L, et al
    Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01734.
    PubMed    
    
    
    
46. YANG JC, Scordo M, Chau KW, Sauter CS, et al
    Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy.
    Bone Marrow Transplant. 2022;57:1038-1041.
    PubMed    
    
    
    May 2022
47. FERNANDEZ-SOJO J, Cid J, Azqueta C, Valdivia E, et al
    Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation.
    Bone Marrow Transplant. 2022 May 25. pii: 10.1038/s41409-022-01722.
    PubMed    
    
    
    
48. ANGELOV D, Dillon J, Mellerick L, Pender E, et al
    Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease.
    Bone Marrow Transplant. 2022 May 20. pii: 10.1038/s41409-022-01713.
    PubMed    
    
    
    
49. FRIETSCH JJ, Miethke J, Linke P, Crodel CC, et al
    Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2022 May 10. pii: 10.1038/s41409-022-01701.
    PubMed     Abstract available
    
    
    April 2022
50. SCHENONE L, Houillier C, Tanguy ML, Choquet S, et al
    Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone Marrow Transplant. 2022 Apr 14. pii: 10.1038/s41409-022-01648.
    PubMed     Abstract available
    
    
    
51. LIU H, Liu W, Li R, Jiao Y, et al
    A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
    Bone Marrow Transplant. 2022 Apr 7. pii: 10.1038/s41409-022-01655.
    PubMed    
    
    
    
52. HEINI AD, Bacher U, Kronig MN, Wiedemann G, et al
    Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center.
    Bone Marrow Transplant. 2022 Apr 5. pii: 10.1038/s41409-022-01658.
    PubMed    
    
    
    March 2022
53. GALLI E, Sora F, Hohaus S, Bellesi S, et al
    Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.
    Bone Marrow Transplant. 2022 Mar 8. pii: 10.1038/s41409-022-01632.
    PubMed    
    
    
    
54. HERNANDEZ-BOLUDA JC, Pereira A, Zinger N, Gras L, et al
    Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
    Bone Marrow Transplant. 2022;57:416-422.
    PubMed     Abstract available
    
    
    February 2022
55. YOON SE, Jo H, Kang ES, Cho D, et al
    Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis.
    Bone Marrow Transplant. 2022 Feb 16. pii: 10.1038/s41409-022-01605.
    PubMed     Abstract available
    
    
    
56. COSTES-TERTRAIS D, Hueso T, Gastinne T, Thieblemont C, et al
    Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
    Bone Marrow Transplant. 2022 Feb 11. pii: 10.1038/s41409-022-01596.
    PubMed     Abstract available
    
    
    
57. HUSBY S, Jorgensen GO, Favero F, Jespersen JS, et al
    Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT.
    Bone Marrow Transplant. 2022 Feb 5. pii: 10.1038/s41409-022-01580.
    PubMed    
    
    
    
58. FRIEND BD, Muhsen IN, Patel S, Hill LC, et al
    Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
    Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-022-01599.
    PubMed     Abstract available
    
    
    
59. WALLADBEGI J, Henriksson R, Tavelin B, Svanberg A, et al
    Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.
    Bone Marrow Transplant. 2022;57:191-197.
    PubMed     Abstract available
    
    
    January 2022
60. LIEVIN R, Di Blasi R, Morin F, Galli E, et al
    Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma.
    Bone Marrow Transplant. 2022 Jan 30. pii: 10.1038/s41409-021-01526.
    PubMed     Abstract available
    
    
    November 2021
61. LEAL CTS, Costa LJM, Pereira J, Duarte FB, et al
    Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients.
    Bone Marrow Transplant. 2021 Nov 29. pii: 10.1038/s41409-021-01531.
    PubMed    
    
    
    October 2021
62. DWORKIN ML, Jiang AL, Von Eyben R, Spinner MA, et al
    Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant.
    Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01495.
    PubMed     Abstract available
    
    
    
63. SALVINI M, Maggi F, Damonte C, Mortara L, et al
    Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation.
    Bone Marrow Transplant. 2021 Oct 11. pii: 10.1038/s41409-021-01487.
    PubMed    
    
    
    
64. SELLNER L, Schetelig J, Koster L, Choi G, et al
    Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
    Bone Marrow Transplant. 2021 Oct 7. pii: 10.1038/s41409-021-01490.
    PubMed    
    
    
    
65. MILLARD T, Sammour F, Anthias C, Easdale S, et al
    Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?
    Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01484.
    PubMed    
    
    
    August 2021
66. INOUE Y, Nakano N, Fuji S, Eto T, et al
    Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2021 Aug 31. pii: 10.1038/s41409-021-01445.
    PubMed     Abstract available
    
    
    
67. MUNSHI PN, Hamadani M, Kumar A, Dreger P, et al
    ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
    Bone Marrow Transplant. 2021 Aug 20. pii: 10.1038/s41409-021-01288.
    PubMed     Abstract available
    
    
    
68. TAMAI H, Tajika K, Nakayama K, Arai A, et al
    Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.
    Bone Marrow Transplant. 2021 Aug 12. pii: 10.1038/s41409-021-01432.
    PubMed    
    
    
    
69. CORNILLON J, Daguenet E, Tournilhac O, Blaise D, et al
    Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire.
    Bone Marrow Transplant. 2021 Aug 6. pii: 10.1038/s41409-021-01426.
    PubMed     Abstract available
    
    
    July 2021
70. LEW TE, Cliff ERS, Dickinson M, Tam CS, et al
    T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease.
    Bone Marrow Transplant. 2021 Jul 20. pii: 10.1038/s41409-021-01418.
    PubMed    
    
    
    
71. LOWENBERG B, Kersten MJ, Gale RP, van Oers M, et al
    Professor Anton Hagenbeek 1948-2021: Father of MRD and lymphoma expert.
    Bone Marrow Transplant. 2021 Jul 19. pii: 10.1038/s41409-021-01375.
    PubMed    
    
    
    
72. CORTELAZZO S, Mian M, Evangelista A, Devizzi L, et al
    Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term.
    Bone Marrow Transplant. 2021 Jul 7. pii: 10.1038/s41409-021-01391.
    PubMed    
    
    
    June 2021
73. GEVA M, Pryce A, Shouval R, Fein JA, et al
    High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2021 Jun 29. pii: 10.1038/s41409-021-01377.
    PubMed     Abstract available
    
    
    
74. BONIFAZI F, Defrancesco I, Olivieri J, Barbato F, et al
    Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas.
    Bone Marrow Transplant. 2021 Jun 9. pii: 10.1038/s41409-021-01359.
    PubMed    
    
    
    May 2021
75. VIJENTHIRA A, Kuruvilla J, Prica A
    Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.
    Bone Marrow Transplant. 2021 May 13. pii: 10.1038/s41409-021-01327.
    PubMed     Abstract available
    
    
    
76. DERENZINI E, Tabanelli V, Sammassimo S, Mazzara S, et al
    Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma.
    Bone Marrow Transplant. 2021 May 7. pii: 10.1038/s41409-021-01320.
    PubMed    
    
    
    April 2021
77. TOYODA K, Yasunaga JI, Choi I, Suehiro Y, et al
    The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Apr 29. pii: 10.1038/s41409-021-01311.
    PubMed    
    
    
    
78. EYRE TA, Caillard S, Finel H, Boumendil A, et al
    Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
    Bone Marrow Transplant. 2021 Apr 16. pii: 10.1038/s41409-021-01270.
    PubMed     Abstract available
    
    
    
79. SHAPIRO LC, Mustafa J, Lombardo A, Khatun F, et al
    Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
    Bone Marrow Transplant. 2021 Apr 12. pii: 10.1038/s41409-021-01280.
    PubMed    
    
    
    March 2021
80. PYTLIK R, Vackova B, Konirova E, Trnkova M, et al
    Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.
    Bone Marrow Transplant. 2021;56:709-712.
    PubMed    
    
    
    February 2021
81. PRINCE HM, Abeyakoon C
    Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sezary syndrome: never-late, never-never?
    Bone Marrow Transplant. 2021 Feb 1. pii: 10.1038/s41409-020-01150.
    PubMed    
    
    
    June 2020
82. MERLI M, Luminari S, Farina L, Cocito F, et al
    Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi.
    Bone Marrow Transplant. 2020 Jun 15. pii: 10.1038/s41409-020-0967.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Malignant Lymphoma is free of charge.